Enron Mail

From:james.derrick@enron.com
To:dtomlin@bcm.tmc.edu
Subject:RE: Committee of 12 -- May 1st Luncheon
Cc:
Bcc:
Date:Tue, 20 Mar 2001 15:12:05 -0800 (PST)

Dalton, I have just returned to the office from a business trip to London of almost two weeks and found your messsage. I think it would be very interesting to hear from Dr. Brenner. All the best. Jim

-----Original Message-----
From: "Tomlin, Dalton" <dtomlin@bcm.tmc.edu<@ENRON [mailto:IMCEANOTES-+22Tomlin+2C+20Dalton+22+20+3Cdtomlin+40bcm+2Etmc+2Eedu+3E+40ENRON@ENRON.com]
Sent: Monday, March 12, 2001 4:53 PM
To: Britton White (E-mail); C. Burton Branstetter (E-mail); Catherine A. Lamboley (E-mail); David B. Garten (E-mail); Hugh Rice Kelly (E-mail); Jack Lynch (E-mail); Jeffery A. Smisek (E-mail); Derrick Jr., James; Kenneth E. Randolph (E-mail); Kerry A. Galvin (E-mail); L. David Hanower (E-mail); Mark S. Berg (E-mail); Michael G. McQueeney (E-mail); Peter W. Arbour (E-mail); Rick A. Harrington (E-mail); Robert D. Kilpatrick (E-mail); Robert Whilden (E-mail); Theodore M. Frois (E-mail); Thomas P. Battle (E-mail); William C. Lemmer (E-mail); William F. Schwind Jr. (E-mail)
Subject: Committee of 12 -- May 1st Luncheon

I am mindful that our guest speakers are ordinarily involved in the
legal profession in some manner. Due to the May 1st date falling in the
final days of the legislative session, my efforts to get one of our key
legislators to speak in Houston on that day have been unavailing (all would
be anxious to do so at some later date).
Consequently, I have tentatively arranged for Malcolm K. Brenner to
join us that day. Dr. Brenner is a Professor in the Department of
Pediatrics and Medicine, Section of Hematology-Oncology, at Baylor College
of Medicine. Among other duties at the Center for Cell and Gene Therapy at
Baylor, Texas Children's Hospital and The Methodist Hospital, Dr. Brenner is
the Director of the Shell Center for Gene Therapy at Baylor. My thought was
that you might find it interesting to hear what Dr. Brenner has to say about
where we are and where we are going in the field of gene therapy. He
recently made a similar presentation to our Board of Trustees, and it was
very well received.
If anyone thinks it undesirable to depart from past practice in this
way, please say so. Further, I will be happy to have anyone else that you
may suggest join us on May 1st in Dr. Brenner's stead.